MA55082A - Compositions, procédés, et kits pour l'administration de polyribonucléotides - Google Patents

Compositions, procédés, et kits pour l'administration de polyribonucléotides

Info

Publication number
MA55082A
MA55082A MA055082A MA55082A MA55082A MA 55082 A MA55082 A MA 55082A MA 055082 A MA055082 A MA 055082A MA 55082 A MA55082 A MA 55082A MA 55082 A MA55082 A MA 55082A
Authority
MA
Morocco
Prior art keywords
polyribonucleotides
kits
administration
compositions
methods
Prior art date
Application number
MA055082A
Other languages
English (en)
Inventor
Ellese Marie Carmona
Boer Alexandra Sophie De
Roger Joseph Hajjar
Avak Kahvejian
Nicholas Mccartney Plugis
Morag Helen Stewart
Original Assignee
Flagship Pioneering Innovations Vi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations Vi Llc filed Critical Flagship Pioneering Innovations Vi Llc
Publication of MA55082A publication Critical patent/MA55082A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA055082A 2019-03-01 2020-03-01 Compositions, procédés, et kits pour l'administration de polyribonucléotides MA55082A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962812763P 2019-03-01 2019-03-01

Publications (1)

Publication Number Publication Date
MA55082A true MA55082A (fr) 2022-01-05

Family

ID=70005812

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055082A MA55082A (fr) 2019-03-01 2020-03-01 Compositions, procédés, et kits pour l'administration de polyribonucléotides

Country Status (10)

Country Link
US (1) US20220088049A1 (fr)
EP (1) EP3930683A1 (fr)
JP (1) JP2022523222A (fr)
KR (1) KR20210134716A (fr)
CN (1) CN113543770A (fr)
AU (1) AU2020231349A1 (fr)
CA (1) CA3128615A1 (fr)
IL (1) IL285923A (fr)
MA (1) MA55082A (fr)
WO (1) WO2020180751A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020011670A2 (pt) 2017-12-15 2020-11-17 Flagship Pioneering Innovations Vi, Llc. composições compreendendo polirribonucleotídeos circulares e seus usos
CA3239266A1 (fr) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Compositions immunogenes de coronavirus et leurs utilisations
CA3238735A1 (fr) 2021-11-24 2023-06-01 Jennifer A. Nelson Compositions immunogenes et leurs utilisations
AU2022397292A1 (en) 2021-11-24 2024-05-30 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
AR128002A1 (es) 2021-12-17 2024-03-20 Flagship Pioneering Innovations Vi Llc Métodos de enriquecimiento de rna circular en condiciones desnaturalizantes
WO2023122789A1 (fr) 2021-12-23 2023-06-29 Flagship Pioneering Innovations Vi, Llc Polyribonucléotides circulaires codant pour des polypeptides antifusogènes

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
EP0542874A4 (en) 1990-07-25 1994-05-11 Syngene Inc Circular extension for generating multiple nucleic acid complements
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
CA2118806A1 (fr) 1991-09-18 1993-04-01 William J. Dower Methode pour la synthese de diverses series d'oligomeres
CA2127461A1 (fr) 1992-01-13 1993-07-22 Michael D. Been Molecules possedant une activite enzymatique de clivage de l'arn
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5721099A (en) 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5440016A (en) 1993-06-18 1995-08-08 Torrey Pines Institute For Molecular Studies Peptides of the formula (KFmoc) ZZZ and their uses
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5688997A (en) 1994-05-06 1997-11-18 Pharmacopeia, Inc. Process for preparing intermediates for a combinatorial dihydrobenzopyran library
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5688696A (en) 1994-12-12 1997-11-18 Selectide Corporation Combinatorial libraries having a predetermined frequency of each species of test compound
DK0839152T3 (da) 1995-06-21 2002-07-08 Martek Biosciences Corp Kombinatoriske biblioteker af mærkede, biokemiske forbindelser og fremgangsmåde til fremstilling af disse
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US5731423A (en) 1996-03-21 1998-03-24 Transcell Technologies, Inc. Process for preparing sulfoxides
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
US8245708B2 (en) 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
EP2647400A1 (fr) 2002-05-07 2013-10-09 The State University of New York at Stony Brook Dispositifs pour therapie endobronchique ciblée
DE102004025881A1 (de) * 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2007069068A2 (fr) 2005-12-16 2007-06-21 Diatos Conjugués peptidiques de pénétration cellulaire pour la délivrance d'acides nucléiques dans une cellule
KR100859972B1 (ko) 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
WO2010084371A1 (fr) 2009-01-26 2010-07-29 Mitoprod Nouvelles molécules d'arn interférent circulaire
WO2011157713A2 (fr) 2010-06-14 2011-12-22 F. Hoffmann-La Roche Ag Peptides pénétrant dans les cellules et leurs utilisations
ES2938866T3 (es) 2010-08-31 2023-04-17 Glaxosmithkline Biologicals Sa Liposomas pegilados para la administración de ARN que codifica para inmunógeno
SG10201605537XA (en) 2011-07-06 2016-09-29 Novartis Ag Liposomes having useful n:p ratio for delivery of rna molecules
WO2013053481A1 (fr) * 2011-10-11 2013-04-18 Secutech International Pte. Ltd. Diméthylsulfoxyde utilisé comme solvant pour des acides nucléiques
KR20140102759A (ko) * 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9878056B2 (en) * 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US20170281541A1 (en) 2014-09-05 2017-10-05 The Johns Hopkins University Liposome-based mucus-penetrating particles for mucosal delivery
CN105664239B (zh) * 2016-03-23 2018-08-07 成都交大麦迪克科技有限公司 一种自粘附皮肤修复水凝胶的制备方法
KR20210035022A (ko) 2016-12-14 2021-03-31 리간달 인코포레이티드 핵산 및/또는 단백질 적재물 전달을 위한 조성물 및 방법

Also Published As

Publication number Publication date
CN113543770A (zh) 2021-10-22
CA3128615A1 (fr) 2020-09-10
EP3930683A1 (fr) 2022-01-05
JP2022523222A (ja) 2022-04-21
WO2020180751A1 (fr) 2020-09-10
KR20210134716A (ko) 2021-11-10
IL285923A (en) 2021-10-31
AU2020231349A1 (en) 2021-09-23
US20220088049A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
MA55082A (fr) Compositions, procédés, et kits pour l'administration de polyribonucléotides
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA51103A (fr) Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA46479A (fr) Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène
IL280963A (en) Anti-5gdf1 antibodies, compounds and methods of use
WO2017173415A3 (fr) Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
MA48797A (fr) Variants de l'endonucléase cblb , compositions et procédés d'utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA52134A (fr) Compositions et procédés pour l'édition génomique
MA53445A (fr) Procédés et compositions pour la modification de plantes
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
MA53558A (fr) Compositions et procédés pour le traitement d'infections virales
MA54091A (fr) Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
MA50045A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA46109A (fr) Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes
WO2017214458A3 (fr) Anticorps anti-cd98 et conjugués anticorps-médicament
WO2017214462A3 (fr) Anticorps anti-cd98 et conjugués anticorps-médicament
WO2018083539A3 (fr) Compositions d'enrobage et leurs procédés d'utilisation
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d'une inflammation